Vaccines, blood, antisera, toxins and cultures in   Switzerland

Exports In 2022, Switzerland exported $46.7B in Vaccines, blood, antisera, toxins and cultures, making it the 4th largest exporter of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 2nd most exported product in Switzerland. The main destination of Vaccines, blood, antisera, toxins and cultures exports from Switzerland are: United States ($14.2B), Germany ($6.49B), Japan ($3.04B), China ($2.98B), and Spain ($2.62B).

The fastest growing export markets for Vaccines, blood, antisera, toxins and cultures of Switzerland between 2021 and 2022 were United States ($9.43B), Japan ($929M), and China ($502M).

Imports In 2022, Switzerland imported $15B in Vaccines, blood, antisera, toxins and cultures, becoming the 7th largest importer of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 3rd most imported product in Switzerland. Switzerland imports Vaccines, blood, antisera, toxins and cultures primarily from: Germany ($3.88B), United States ($3.62B), Ireland ($2.5B), Japan ($1.17B), and South Korea ($816M).

The fastest growing import markets in Vaccines, blood, antisera, toxins and cultures for Switzerland between 2021 and 2022 were United States ($2.28B), South Korea ($655M), and Germany ($317M).